Is MOTS-c Legal in Texas?

HealthRX.com

Federal rules give MOTS-c no standard compounding pathway

Print or save as PDF

See the public record for MOTS-c

  • FDA approval / None; not part of any approved drug [1]
  • Pharmacy and physician compounding status / In none of the three FDA categories for state-licensed pharmacies and physicians [2][4]
  • Outsourcing facility status / Absent from FDA's outsourcing facility list [3]
  • Safety-risk table / In FDA's 'nominated but withdrawn' table of substances flagged for possible significant safety risks [7]
  • HHS draft policy / Filed October 28, 2026; non-binding; acetate injection only [5][6]
  • Human data / No published study giving MOTS-c to a person [1]
  • Sport / WADA prohibits it at all times under S4.4.1 [8][12]

Is MOTS-c an approved drug?

No. FDA's July 2026 review found no USP or National Formulary monograph, no European or Japanese pharmacopeia listing and no EMA-authorised product [1]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [1][9].

Federal compounding status

FDA says state-licensed physicians and pharmacists may compound only with bulk substances that comply with a USP or National Formulary monograph, are components of FDA-approved drugs, or appear on FDA's bulks list, and that the substance must come with a valid certificate of analysis and be made by an FDA-registered establishment [4]. MOTS-c has no USP or National Formulary monograph, is not a component of an FDA-approved drug, and is not on the bulks list [1][4]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or on FDA's outsourcing facility list, updated March 21, 2025 [2][3][4].

MOTS-c is listed in FDA's 'nominated but withdrawn' table of bulk substances that may present significant safety risks. That table holds substances previously in category 2 whose nominators withdrew them, and removal from category 2 was not a finding that the substance is safe [7]. FDA's stated concerns were that it 'has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration' and that injectable peptides may pose an immunogenicity risk [7]. FDA also states that compounded drugs are not FDA-approved, meaning it does not verify their safety, effectiveness or quality before they are marketed [10]. State boards of pharmacy generally hold primary responsibility for day-to-day oversight of state-licensed pharmacies [10].

Questions worth asking

Choose the questions you want to keep

What changed in 2026

FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the bulks list, citing poor characterisation, unknown compounding use, no human safety or effectiveness data, no animal toxicity studies, and existing approved treatments for obesity and osteoporosis [1]. The Pharmacy Compounding Advisory Committee voted in favour of adding it on July 23, 2026, against staff's recommendation; that vote is advice only and listing takes formal rulemaking [11][5].

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192; publication scheduled October 30, 2026, with comments due two weeks after publication), naming MOTS-c among six peptides and covering the acetate form given by subcutaneous or intramuscular injection [5]. Under it HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds it when conditions such as a single active ingredient, a patient-specific prescription, and an FDA-registered manufacturer with a certificate of analysis are met [5][6]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [5].

What is known about human use

FDA found no published study in which MOTS-c was given to a person, and there is no approved dose; the nominated products were 5 mg and 10 mg subcutaneous injections [1]. The reported metabolic effects, such as less weight gain on a high-fat diet, come from mouse studies [9], and FDA found no pharmacokinetic data in humans [1]. WADA lists MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times [8][12].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what must a bulk substance come with for state-licensed pharmacists to compound it?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is MOTS-c legal in Texas?
This page cannot say what Texas law allows. Federally, MOTS-c is not FDA-approved, appears in none of the three FDA categories for compounding a bulk substance, and is absent from the outsourcing facility list, so there is no standard federal pathway [1][2][3][4]. The October 2026 HHS enforcement-discretion policy is a non-binding draft limited to MOTS-c acetate injection under stated conditions [5][6].
Can a Texas doctor prescribe MOTS-c?
Texas prescribing rules are not established here. Federally, MOTS-c is in none of the three FDA categories for state-licensed pharmacies and physicians and is absent from the outsourcing facility list [2][3][4]. The draft HHS policy addresses compounding by licensed physicians and pharmacies of MOTS-c acetate injection when its conditions are met, and it is not binding [5][6].
Does the HHS policy make MOTS-c legal?
No. It is a draft statement that HHS does not intend to take enforcement action in defined circumstances for the acetate form given by injection. It does not put MOTS-c on any FDA list, does not approve it, and says it 'does not establish any rights for any person and is not binding on HHS or the public' [5][6].
Show all 12 referencesHide references
Evidence overview for Is MOTS-c Legal in Texas?